Professor Jose Polo

PROFESSOR

  • jose.polo@monash.edu

Biography

Jose Maria Polo was born in Buenos Aires, Argentina where he graduated from Buenos Aires University as a Biochemist. In 2002, Jose began his graduate studies at Albert Einstein College of Medicine, New York under the supervision of Dr Ari Melnick where he worked on the transcriptional mechanism of the BCL6 repression complex in B-cell lymphomas and B-cell maturation. In 2008, he obtained his PhD and moved to Boston to the laboratory of Dr Konrad Hochedlinger at the Harvard Stem Cell Institute to work on reprogramming of adult cells into induced pluripotent stem (iPS) cells. In particular, his work focused on the acquisition of immortality and the existence of epigenetic memory during reprogramming.

In June 2011, established his independent research group at Monash University, where he held appointments with the departments of Anatomy and Developmental Biology and with the Australian Regenerative Medicine Institute (ARMI). In 2012, Jose was awarded a NHMRC Career Development Fellowship, in 2014 a Silvia and Charles Viertel Senior Medical Research Fellowship. In 2016, he co-founded Mogrify Ltd to translate reprogramming technologies into therapies, receiving several accolades including a Future Fellowship in 2018 and the 2019 Scrip Innovation Award. Professor Polo remains a group leader at ARMI part-time.

In October 2021, Jose was recruited to the University of Adelaide as the inaugural Director of the Adelaide Centre for Epigenetics (ACE) and group leader of the recently established South Australian Immunogenomics Cancer Institute (SAiGENCI). In Adelaide, Professor Polo continues his work in epigenetics and its application to reprogramming, early embryogenesis and cancer. His work in epigenetics, reprogramming and cancer has been published in journals such as Nature, Cell, Nature Genetics, Cell Stem Cell and Nature Medicine among others as well as recognised with several awards including the Merit Award from the American Society of Haematology, the inaugural Metcalf Award, Victorian Young Tall Poppy Award, the Monash’s Vice-Chancellor award.

Click here for full list of publications on ORCID

Research interests

The Polo group is interested in the transcriptional and epigenetic mechanisms that govern cell identity, in particular pluripotency, reprogramming of somatic cells into induced pluripotent stem (iPS) cells, development and cancer.

Being able to reprogram any specific mature cellular program into a pluripotent state and from there back into any other particular cellular program provides a unique tool to dissect the molecular and cellular events that permit the conversion of one cell type to another. Moreover, iPS cells and the reprogramming technology are of great interest in pharmaceutical and clinical settings, since the technology can be used to generate animal and cellular models for the study of various diseases as well in the future to provide specific patient tailor made cells for their use in cellular replacement therapies. By using a broad array of approaches through the use of mouse and human stem cells models combined with different molecular, biochemical, cellular techniques and genome wide approaches, our lab will aim to dissect the nature and dynamics of such events. Understanding the events leading to the generation of iPS cells has allowed us to not only she light into this process but it has led to the generation of complex models of humans development. Furthermore, we are using and translating the tools and knowledge gained through this work into the fields of development, cancer and several other diseases.

We are particularly interested in the following aspects:

1) The kinetics and universality of the epigenetic and genomic changes occurring during cell fate transitions.

2) The composition and assembly kinetics of transcriptional regulation complexes at pluripotency genes and cancer associated transcription factors.

3) How the cell of origin influences the in vitro and in vivo plasticity potential of cells generated during the reprogramming process.

4) The role of transcription factors in cancer initiation and progression

5) Understanding mammalian development through the use of complex in vitro models

6) Synthetic cell biology

Source: Prof Jose Polo | Researcher Profiles | Adelaide University

Featured Publications

Authors Title Published In

Knaupp AS, Buckberry S, Pflueger J, Lim SM, Ford E, Larcombe MR, Rossello FJ, de Mendoza A, Alaei S, Firas J, Holmes ML, Nair SS, Clark SJ, Nefzger CM, Lister R, Polo JM.

Transient and permanent reconfiguration of chromatin and transcription factor occupancy drive reprogramming.

Cell Stem Cell. 2017 Dec 7;21(6):834-845.e6. doi: 10.1016/j.stem.2017.11.007.

Nefzger CM, Rossello FJ, Chen J, Liu X, Knaupp AS, Firas J, Paynter JM, Pflueger J, Buckberry S, Lim SM, Williams B, Alaei S, Faye-Chauhan K, Petretto E, Nilsson SK, Lister R, Ramialison M, Powell DR, Rackham OJL, Polo JM.

Cell type of origin dictates the route to pluripotency.

Cell Rep. 2017 Dec 5;21(10):2649-2660. doi: 10.1016/j.celrep.2017.11.029.

Liu X, Nefzger CM, Rossello FJ, Chen J, Knaupp AS, Firas J, Ford E, Pfleuger J, Paynter JM, Chy HS, O’Brien CM, Huang C, Mishra K, Hodgson-Garms M, Jansz N, Williams SM, Blewitt ME, Nilsson SK, Schittenhelm RB, Laslett AL, Lister R, Polo JM.

Comprehensive characterization of distinct states of human naive pluripotency generated by reprogramming.x

Nat Methods. 2017 Nov;14(11):1055-1062. doi: 10.1038/nmeth.4436. Epub 2017 Sep 25.

Firas J, Polo JM.

Towards understanding transcriptional networks in cellular reprogramming.

Curr Opin Genet Dev. 2017 Oct;46:1-8. doi: 10.1016/j.gde.2017.06.001. Epub 2017 Jun 21.

Nguyen PD, Gurevich DB, Sonntag C, Hersey L, Alaei S, Nim HT, Siegel A, Hall TE, Rossello FJ, Boyd SE, Polo JM, Currie PD.

Muscle stem cells undergo extensive clonal drift during tissue growth via Meox1-Mediated induction of G2 cell-cycle arrest.

Cell Stem Cell. 2017 Jul 6;21(1):107-119.e6. doi: 10.1016/j.stem.2017.06.003.

Mariño E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, McKenzie C, Kranich J, Oliveira AC, Rossello FJ, Krishnamurthy B, Nefzger CM, Macia L, Thorburn A, Baxter AG, Morahan G, Wong LH, Polo JM, Moore RJ, Lockett TJ, Clarke JM, Topping DL, Harrison LC, Mackay CR.

Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes.

Nat Immunol. 2017 May;18(5):552-562. doi: 10.1038/ni.3713. Epub 2017 Mar 27.

Nefzger CM, Polo JM.

DEAD-Box RNA binding protein DDX5: Not a black-box during reprogramming.

Cell Stem Cell. 2017 Apr 6;20(4):419-420. doi: 10.1016/j.stem.2017.03.006.

Liu X, Chen J, Firas J, Paynter JM, Nefzger CM, Polo JM.

Generation of mouse induced pluripotent stem cells by lentiviral transduction.

Methods in Molecular Biology 2017 (in press).

Rackham OJ, Firas J, Fang H, Oates ME, Holmes ML, Knaupp AS; FANTOM Consortium, Suzuki H, Nefzger CM, Daub CO, Shin JW, Petretto E, Forrest AR, Hayashizaki Y, Polo JM, Gough J.

A predictive computational framework for direct reprogramming between human cell types.

Nat Genet. 2016 Mar;48(3):331-5. doi: 10.1038/ng.3487. Epub 2016 Jan 18.

Nefzger CM, Jardé T, Rossello FJ, Horvay K, Knaupp AS, Powell DR, Chen J, Abud HE, Polo JM.

A versatile strategy for isolating a highly enriched population of inteistinal stem cells. 

Stem Cell Reports. 2016 Feb 18. doi: 10.1016/j.stemcr.2016.01.014. [Epub ahead of print]

Nefzger CM, Alaei S, Polo JM.

Isolation of reprogramming intermediates during generation of induced pluripotent stem cells from mouse embryonic fibroblasts.

Methods Mol Biol. 2015;1330:205-18. doi: 10.1007/978-1-4939-2848-4_17.

Hobbs RM, Polo JM.

Reprogramming can be a transforming experience.

Cell Stem Cell. 2014 Mar 6;14(3):269-71. doi: 10.1016/j.stem.2014.02.003.

Apostolou E, Ferrari F, Walsh RM, Bar-Nur O, Stadtfeld M, Cheloufi S, Stuart HT, Polo JM, Ohsumi TK, Borowsky ML, Kharchenko PV, Park PJ, Hochedlinger K.

Genome-wide Chromatin Interactions of the Nanog Locus in Pluripotency, Differentiation, and Reprogramming.

Cell Stem Cell. 2013 Jun 6;12(6):699-712. doi: 10.1016/j.stem.2013.04.013. Epub 2013 May 9.

Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM, Kormaksson M, MacKerell AD Jr, Xue F, Mason CE, Hiebert SW, Prive GG, Cerchietti L, Bardwell VJ, Elemento O, Melnick A.

A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.

Cell Rep. 2013 Aug 15;4(3):578-88. doi: 10.1016/j.celrep.2013.06.016. Epub 2013 Aug 1.

Kaur G, Costa MW, Nefzger CM, Silva J, Polo JM, Bell TDM, Plachta N.

Quantifying transcription factor diffusion in the living mammalian embryo by photoactivatable FCS.

Nat Comm 2013. doi: 10.1038/ncomms2657

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F.

Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.

PLoS Genet. 2013;9(1):e1003137. doi: 10.1371/journal.pgen.1003137. Epub 2013 Jan 10.

Kelly RD, Rodda AE, Dickinson A, Mahmud A, Nefzger CM, Lee W, Forsythe J, Polo JM, Trounce IA, McKenzie M, Nisbet DR, St John JC.

Mitochondrial DNA haplotypes define gene expression patterns in pluripotent and differentiating embryonic stem cells.

Stem Cells. 2013 Apr;31(4):703-16. doi: 10.1002/stem.1313.

Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, Borkent M, Apostolou E, Alaei S, Cloutier J, Bar-Nur O, Cheloufi S, Stadtfeld M, Figueroa ME, Robinton D, Natesan S, Melnick A, Zhu J, Ramaswamy S, Hochedlinger K.

A molecular roadmap of reprogramming somatic cells into iPS cells.

Cell. 2012 Dec 21;151(7):1617-32. doi: 10.1016/j.cell.2012.11.039.

Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K.

Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells

Nat Biotechnol. 2010 Aug;28(8):848-55. doi: 10.1038/nbt.1667. Epub 2010 Jul 19.

Buecker C, Chen HH, Polo JM, Daheron L, Bu L, Barakat TS, Okwieka P, Porter A, Gribnau J, Hochedlinger K, Geijsen N.

A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells

Cell Stem Cell. 2010 Jun 4;6(6):535-46. doi: 10.1016/j.stem.2010.05.003.

Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborán IM, Melnick AM, Ye BH, Müschen M.

BCL6 is critical for the development of a diverse primary B cell repertoire

J Exp Med. 2010 Jun 7;207(6):1209-21. doi: 10.1084/jem.20091299. Epub 2010 May 24.

Utikal J and Polo JM*, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. (*:Co- First Author).

Immortalization eliminates a roadblock during cellular reprogramming into iPS cells

Nature. 2009 Aug 27;460(7259):1145-8. doi: 10.1038/nature08285. Epub 2009 Aug 9.